- Home
- SBSW vs CGON Comparison
SBSW vs CGON Comparison
Compare SBSW & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBSW
- CGON
- Stock Information
- Founded
- SBSW 2013
- CGON 2010
- Country
- SBSW South Africa
- CGON United States
- Employees
- SBSW N/A
- CGON 61
- Industry
- SBSW Precious Metals
- CGON
- Sector
- SBSW Basic Materials
- CGON
- Exchange
- SBSW Nasdaq
- CGON NYSE
- Market Cap
- SBSW 3.0B
- CGON 2.2B
- IPO Year
- SBSW N/A
- CGON 2024
- Fundamental
- Price
- SBSW $3.98
- CGON $32.84
- Analyst Decision
- SBSW Hold
- CGON Strong Buy
- Analyst Count
- SBSW 4
- CGON 8
- Target Price
- SBSW $4.98
- CGON $63.88
- AVG Volume (30 Days)
- SBSW 8.0M
- CGON 396.6K
- Earning Date
- SBSW 11-29-2024
- CGON 11-12-2024
- Dividend Yield
- SBSW 9.50%
- CGON N/A
- EPS Growth
- SBSW N/A
- CGON N/A
- EPS
- SBSW N/A
- CGON N/A
- Revenue
- SBSW $5,933,684,244.00
- CGON $684,000.00
- Revenue This Year
- SBSW N/A
- CGON $411.76
- Revenue Next Year
- SBSW $5.67
- CGON $405.27
- P/E Ratio
- SBSW N/A
- CGON N/A
- Revenue Growth
- SBSW N/A
- CGON 258.12
- 52 Week Low
- SBSW $3.08
- CGON $25.77
- 52 Week High
- SBSW $5.93
- CGON $50.23
- Technical
- Relative Strength Index (RSI)
- SBSW 39.99
- CGON 41.08
- Support Level
- SBSW $3.99
- CGON $35.12
- Resistance Level
- SBSW $4.21
- CGON $40.47
- Average True Range (ATR)
- SBSW 0.22
- CGON 1.69
- MACD
- SBSW -0.11
- CGON -0.28
- Stochastic Oscillator
- SBSW 3.31
- CGON 4.57
About SBSW D/B/A Sibanye-Stillwater Limited ADS
Sibanye Stillwater Ltd is a South African mining and metals processing group with a diverse portfolio of operations, projects, and investments across five continents. The Group is also one of the foremost recyclers of PGM autocatalysts and has interests in mine tailings retreatment operations. It is a producer of platinum, palladium, and rhodium and is a top-tier gold producer. It also produces and refines iridium and ruthenium, nickel, chrome, copper, and cobalt. Its products are Gold, Nickel, Zinc, Chrome, PGMs, and other.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.